Patents Issued in December 7, 2017
  • Publication number: 20170348367
    Abstract: Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.
    Type: Application
    Filed: April 12, 2017
    Publication date: December 7, 2017
    Inventors: Cheng HUANG, Keng-Chang TSAI, Yu-Ling HUANG, Ming-Jaw DON, Hsiu-Chen HUANG, Wang-Chuan CHEN, Hui-Kang LIU
  • Publication number: 20170348368
    Abstract: A composition having an extract of seed of Emblica officinalis. Methods of preparing extract of seed of Emblica officinalis. An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis. Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing HDL-C levels, increasing the HDL-C level to total cholesterol ratio, lowering LDL-C levels, decreasing the CRP level, decreasing the intima media thickening, reducing hair fall in mammals especially human beings. The extract of seed of Emblica officinalis, or the amla seed blend composition is more effective compared to extracts prepared from fruits of Emblica officinalis.
    Type: Application
    Filed: August 23, 2017
    Publication date: December 7, 2017
    Inventor: Benny Antony
  • Publication number: 20170348369
    Abstract: The present invention is directed to a composition comprising an aqueous and/or organic extract of at least one Chamomilla plant and/or of at least one Achillea plant for the treatment of an abnormal proliferative and/or viral condition, with the proviso that for the treatment of said abnormal proliferative condition the mono/single extract of Achillea millefolium (L.) is excluded, and with the further proviso that for the treatment of said viral condition the mono/single extract of Matricaria chamomilla (L.) is excluded.
    Type: Application
    Filed: July 18, 2017
    Publication date: December 7, 2017
    Inventor: Matthias-Heinrich Kreuter
  • Publication number: 20170348370
    Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.
    Type: Application
    Filed: June 6, 2016
    Publication date: December 7, 2017
    Applicant: CHARSIRE BIOTECHNOLOGY CORP.
    Inventor: CHU I-HUNG
  • Publication number: 20170348371
    Abstract: It has been discovered that the formulation of Nigella Sativa together with solvents had antineoplastic efficiency on cancerous cells. This formulation has been examined with DMSO and Alcoholic solvents in-vitro. The EC50 dose on Hep2 cells have been calculated as 500 ?g/ml. Higher doses have also been found to be efficient as long as the DMSO content was also increased. The formulation has also been found to be efficient in comparison to reference medicines used in present treatments against Toxoplasma gondii which is a protozoon and it has also been noted that the formulation inhibited the reproduction of and eliminated Toxoplasma gondii. It has been discovered that it is effective on gram positive, gram negative micro organisms, fungi and parasites.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 7, 2017
    Inventor: Baris DUZGUN
  • Publication number: 20170348372
    Abstract: Disclosed are an acne-removing traditional Chinese medicine composition and a preparation method thereof, wherein the traditional Chinese medicine composition is made from Garcinia mangostana L pericarp, thyme and Fructus aurantii through steps of ethanol extraction and macroporous resin, and collecting the part eluted by 60%-80% ethanol. The three medicinal materials of the composition have a synergic anti-inflammation effect.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 7, 2017
    Applicant: INFINITUS (CHINA) COMPANY LTD
    Inventors: Guangrong LIU, Wenjuan DENG, Jian TANG
  • Publication number: 20170348373
    Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives.
    Type: Application
    Filed: June 13, 2017
    Publication date: December 7, 2017
    Inventors: T.G. SAMBANDAN, ChoKyun RHA, Anthony J. SINSKEY, Ravigadevi SAMBANTHAMURTHI, Yew Ai TAN, Kalyana Sundram P. MANICKAM, Mohd Basri WAHID
  • Publication number: 20170348374
    Abstract: It has been discovered that the formulation of Ginger (Zingiber officinale) together with solvents had antineoplastic efficiency on cancerous cells. This formulation has been examined with DMSO and Alcoholic solvents in-vitro. The EC50 dose on Hep2 cells has been calculated as 800 ?g/ml. Higher doses have also been found to be efficient as long as the DMSO content was also increased. The formulation has also been found to be efficient in comparison to reference medicines used in present treatments against Toxoplasma gondii which is a protozoon and it has also been noted that the formulation inhibited the reproduction of and eliminated Toxoplasma gondii. It has been discovered that it is effective on gram positive, gram negative microorganisms, fungi and parasites.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 7, 2017
    Inventor: Baris DUZGUN
  • Publication number: 20170348375
    Abstract: Haematopoietic stem cell mobilization is a process whereby haematopoietic stem cells are stimulated out of the bone marrow space. Before HSC can mobilize, they must be dislodged and released from the BM stem cell niche in which they reside and are retained by adhesive interactions. Accordingly, in an aspect of the present invention there is provided a method for enhancing dislodgement of HSC and their precursors and progenitors thereof from a BM stem cell binding ligand in vivo or ex vivo, said method comprising administering in vivo or ex vivo an effective amount of an antagonist of an a 9 integrin or an active portion thereof to the BM stem cell niche. Once mobilized to the peripheral blood (PB) the HSC may be collected for transplant. Methods which enhance mobilization of the HSC can also improve treatments of haematological disorders.
    Type: Application
    Filed: December 12, 2014
    Publication date: December 7, 2017
    Inventors: Susan Kaye NILSSON, David Norman HAYLOCK, Benjamin Ben Ming CAO
  • Publication number: 20170348376
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Christopher Paul LEAMON, Joseph Anand REDDY, Binh NGUYEN, Alicia BLOOMFIELD, Melissa NELSON, Ryan DORTON
  • Publication number: 20170348377
    Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.
    Type: Application
    Filed: August 10, 2016
    Publication date: December 7, 2017
    Applicant: Regents of the University of Colorado, a body corporate
    Inventors: Martha Karen Newell-Rogers, Evan Newell
  • Publication number: 20170348378
    Abstract: Methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.
    Type: Application
    Filed: April 21, 2017
    Publication date: December 7, 2017
    Inventors: David M. RYCKMAN, Iching G. YU
  • Publication number: 20170348379
    Abstract: The present invention generally relates to systems and methods for the transdermal delivery of the heptapeptide ZW1. In some aspects, ZW1 may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: June 14, 2017
    Publication date: December 7, 2017
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20170348380
    Abstract: The present invention relates to pharmaceutical preparations and medicaments for intraarticular administration, comprising pepstatin, and to the preparation and use thereof, in particular in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia, particularly preferably in arthrosis.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 7, 2017
    Applicant: Merck Patent GmbH
    Inventors: Markus KLEIN, Ralf WODOPIA, Hans GUEHRING, Sven LINDEMANN
  • Publication number: 20170348381
    Abstract: The present disclosure relates to an aqueous composition of an antifungal peptide, to methods of treatment using the composition and to uses of the composition.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 7, 2017
    Inventor: Deborah O'NEIL
  • Publication number: 20170348382
    Abstract: The present invention relates to lyophilized compositions comprising daptomycin or pharmaceutically acceptable salts or solvates thereof with improved reconstitution time for parenteral administration and the processes for preparation thereof.
    Type: Application
    Filed: December 16, 2015
    Publication date: December 7, 2017
    Inventors: Sushil KURADE, Sachin Appasaheb SURWASE, Somashekhar BATTINI, Bhushan Subhash YEOLA, Harshal BHAGWATWAR
  • Publication number: 20170348383
    Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 7, 2017
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Anthony COATES, Yanmin HU
  • Publication number: 20170348384
    Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 7, 2017
    Inventor: Benjamin S. Bleier
  • Publication number: 20170348385
    Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
    Type: Application
    Filed: November 6, 2015
    Publication date: December 7, 2017
    Inventors: IVONA JASPRICA, SABINA KESER, KATARINA PINDRIC
  • Publication number: 20170348386
    Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.
    Type: Application
    Filed: January 16, 2017
    Publication date: December 7, 2017
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Beverly L. Davidson, Yong Hong Chen
  • Publication number: 20170348387
    Abstract: Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with Leber congenital amaurosis (LCA) in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal NPHP5 protein, or fragment thereof, under the control of regulatory sequences which express the NPHP5 protein in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 28, 2017
    Publication date: December 7, 2017
    Inventors: Gustavo Aguirre, William A. Beltran, Samuel G. Jacobson, Artur V. Cideciyan, William W. Hauswirth, Sanford L. Boye
  • Publication number: 20170348388
    Abstract: Adjuvants acting at the level of antigen presentation useful for stimulation of specific immunity against tumor endothelial cells. In one embodiment the invention teaches the use of activation of specific antigen presenting cell programs to selectively induce cytotoxic T cells and antibodies with complement activating ability while not evoking antigenic responses that potentially stimulate angiogenesis or growth of tumor endothelial cells. Specifically, the invention teaches selection and use of adjuvants that inhibit suppressive dendritic cell produced factors, surface bound and soluble, while stimulating activatory cytokines. Adjuvant means include innate activatory molecules, gene silencing means, alarmins, and other stimulatory means resembling “danger” signals.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Applicant: Batu Biologics, Inc.
    Inventors: Samuel C. Wagner, Thomas E. Ichim
  • Publication number: 20170348389
    Abstract: Methods of treating liver diseases such as liver fibrosis using an interleukin 24 (IL-24) protein.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 7, 2017
    Applicant: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Publication number: 20170348390
    Abstract: Cancer is a complex group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Described herein are compositions and methods for the treatment of cancer.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Inventors: Raymond Wong, Robert Cameron
  • Publication number: 20170348391
    Abstract: The present invention is based, in part, on the identification of iiicihods of using multiple-variable IL-2 doses for identifying, assessing, preventing, and treating immune disorders.
    Type: Application
    Filed: October 7, 2015
    Publication date: December 7, 2017
    Inventors: John Koreth, Robert J. Soiffer, Jerome Ritz
  • Publication number: 20170348392
    Abstract: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 7, 2017
    Inventors: Catherine M. ROHLOFF, Guohua CHEN, Andrew S. LUK, Rupal A. Ayer, Paul R. Houston, Michael A. Desjardin, Pauline Zamora, Stan Lam
  • Publication number: 20170348393
    Abstract: A method of upregulating an anti-inflammatory response in a central nervous system (CNS) of a subject in need thereof is disclosed. The method comprising locally administering to the CNS of the subject a therapeutically effective amount of IFN-beta, thereby upregulating the anti-inflammatory response in the CNS of the subject. Methods of treating an inflammation in a CNS or treating a disease, disorder, condition or injury of a CNS of a subject are also disclosed.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 7, 2017
    Inventors: Michal SCHWARTZ-EISENBACH, Ido AMIT, Merav COHEN, Orit MATCOVICH
  • Publication number: 20170348394
    Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, includes at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions include, in addition, a gastrointestinal hormone.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Applicant: ADOCIA
    Inventor: Alexandre GEISSLER
  • Publication number: 20170348395
    Abstract: An injectable aqueous solution, the pH of which is from 6.0 to 8.0, having at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions have, in addition, a gastrointestinal hormone.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Applicant: ADOCIA
    Inventor: Alexandre GEISSLER
  • Publication number: 20170348396
    Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, a prandial insulin or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Applicant: ADOCIA
    Inventor: Alexandre GEISSLER
  • Publication number: 20170348397
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • Publication number: 20170348398
    Abstract: Disclosed are improved compositions and methods for decreasing blood glucagon levels. As disclosed herein, L-glutamine is a selective stimulator of ?-cell proliferation generated when glucagon signaling is interrupted. Therefore, disclosed is a method for treating a subject with hyperglucagonemia, e.g., a subject with diabetes, that involves administering to the subject a composition comprising an L-glutamine inhibitor in an amount effective to decrease blood glucagon levels.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 7, 2017
    Inventors: Alvin C. Powers, Erika Danielle Dean
  • Publication number: 20170348399
    Abstract: The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and lactoperoxidase and/or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.3 to 20.
    Type: Application
    Filed: August 23, 2017
    Publication date: December 7, 2017
    Applicant: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Aiko OHMACHI, Hiroaki MATSUYAMA, Yoshikazu MORITA, Yuko ISHIDA, Takayuki NARA, Ken KATO, Atsushi SERIZAWA
  • Publication number: 20170348400
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Application
    Filed: January 6, 2017
    Publication date: December 7, 2017
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda Guth, Leah Mitchell
  • Publication number: 20170348401
    Abstract: Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention, comprising a molar excess of fatty acids in the stabilizing envelope, are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 7, 2017
    Applicant: BRACCO SUISSE S.A.
    Inventors: Gilles BIOLEY, Philippe BUSSAT, Blaise CORTHESY, Anne LASSUS
  • Publication number: 20170348402
    Abstract: It has been established that bacterial hybrid vectors including prokaryote cells modified by the addition of cationic polymers to the outer surface of the cell can selectively deliver exogenous cargos, such as nucleic acids, polypeptides and small molecules to an eukaryotic cell, such as an antigen presenting cell. Compositions and methods for the delivery and expression of nucleic acids and polypeptides to eukaryotic cells are described. The bacterial hybrid vectors include one or more cationic polymers that enhance uptake by antigen presenting cells. The hybrid bacterial vectors include expression vectors that express one or more factors to enhance lysosomal escape and cytosolic delivery of cargo. The vectors are useful as adjuvants to stimulate and/or induce immune responses to any desired antigen, to develop a protective immune response in a subject.
    Type: Application
    Filed: July 30, 2015
    Publication date: December 7, 2017
    Inventors: Blaine A. Pfeifer, Charles Jones
  • Publication number: 20170348403
    Abstract: The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 7, 2017
    Inventor: Lijun WU
  • Publication number: 20170348404
    Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
    Type: Application
    Filed: June 22, 2017
    Publication date: December 7, 2017
    Inventors: Brian Lichty, Bryam Bridle, Yonghong Wan, Jonathan Bramson
  • Publication number: 20170348405
    Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments.
    Type: Application
    Filed: January 30, 2017
    Publication date: December 7, 2017
    Inventors: Takayuki Shiratsuchi, Moriya Tsuji
  • Publication number: 20170348406
    Abstract: The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is F. psychrophilum and/or infectious pancreatic necrosis virus (IPNV).
    Type: Application
    Filed: April 17, 2017
    Publication date: December 7, 2017
    Inventors: Elizabeth Mary Crump, Jan Burian, Joseph Michale Bricker, William Wayne Kay, Norman William Johnson
  • Publication number: 20170348407
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Application
    Filed: August 17, 2017
    Publication date: December 7, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Vega MASIGNANI, Marirosa MORA, Maria SCARSELLI
  • Publication number: 20170348408
    Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 7, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco BERTI, Paolo COSTANTINO, Maria Rosaria ROMANO
  • Publication number: 20170348409
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Application
    Filed: May 12, 2017
    Publication date: December 7, 2017
    Inventor: Daral John Jackwood
  • Publication number: 20170348410
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Application
    Filed: August 16, 2017
    Publication date: December 7, 2017
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus VAN DER BURG, Gemma G. KENTER, Cornelis Johannes Maria MELIEF
  • Publication number: 20170348411
    Abstract: The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.
    Type: Application
    Filed: October 6, 2015
    Publication date: December 7, 2017
    Inventors: Rajeev Mhalasakant DHERE, Sambhaji Shankar PISAL, Jagdish Kamalaji ZADE, Rajendra Narayan SABALE
  • Publication number: 20170348412
    Abstract: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, Alzheimer's disease, ALS, Guillain-Barre syndrome, atherosclerosis, schizophrenia, Tremors/Parkinson's disease, senile dementia, Muscular Dystrophy, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Complex Regional Pain Syndrome, Diabetes, Neuropathic Pain, Spider Arthritis West Nile Virus,, Fibromyalgia, Shingles, Gout, Migraine Headaches, Post Polio Syndrome, Central Virus Deafness, Asthma, Chronic Pain Of Unknown Origin and Hepatitis C and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostate cancer and others realized immediate beneficial results with no side effects.
    Type: Application
    Filed: August 22, 2017
    Publication date: December 7, 2017
    Applicant: HONOR C.W. M.D., LLC
    Inventor: George Nelson
  • Publication number: 20170348413
    Abstract: The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, namely of a clade different from clade 1 or from any clade with the exception of clade 1, respectively.
    Type: Application
    Filed: July 28, 2017
    Publication date: December 7, 2017
    Inventors: Mauricio REALPE-QUINTERO, Paulino Carlos GONZALEZ-HERNANDEZ, Eric VAUGHN
  • Publication number: 20170348414
    Abstract: Described herein are compounds for use in vaccine compositions which contain natural or synthetic carbohydrate antigens. Such vaccines may be highly immunologically active due to the conjugation with an immune-stimulating protein or with a monophosphorylated lipid A derivative, and may be self-adjuvanting due to the presence of a monophosphorylated lipid A derivative. Treatments for cancer and fungal and bacterial infections are described herein.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 7, 2017
    Applicant: Wayne State University
    Inventors: Zhongwu Guo, Guochao Liao, Zhifang Zhou, Mohabul Mondal, Srinivas Burgula
  • Publication number: 20170348415
    Abstract: The invention relates to tolerogenic compositions and methods for the preparation, manufacture and therapeutic use thereof.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 7, 2017
    Inventors: Stephen G. HOGE, Eric Yi-Chun HUANG, Louis Saint Laurence O'DEA
  • Publication number: 20170348416
    Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.
    Type: Application
    Filed: May 14, 2017
    Publication date: December 7, 2017
    Applicant: Ossianix, Inc.
    Inventors: Julien HÄSLER, Julia Lynn RUTKOWSKI, Krzysztof Bartlomiej WICHER